David Tuller
Trial By Error: Some Thoughts on Ten Years of Trial By Error
By David Tuller
By David Tuller, DrPH Ten years ago this month, I launched Trial By Error with a 15,000-word investigation of the misbegotten and fraudulent PACE trial, which purported to prove that graded exercise therapy (GET) and cognitive behavior therapy (CBT) could cure what they then called chronic fatigue syndrome. And what ...
Trial By Error: Dutch Paper on Medical Abuse of Kids Ignores NICE Guidance on ME/CFS-Related Safeguarding Issues
By David Tuller
By David Tuller, DrPH This is a crowdfunding month for UC Berkeley and Trial By Error. If you’d like to support my work, here’s the link. (Donations are tax-deductible for US taxpayers.) ********** The journal Child Abuse & Neglect recently published a paper called “Characteristics of 86 families and 142 ...
Trial By Error: Lancet Journal Agrees to Correct Seriously Flawed Paper on Long COVID Interventions
By David Tuller
By David Tuller, DrPH This is a crowdfunding month for UC Berkekely and Trial By Error. If you’d like to support my work, here’s the link: https://crowdfund.berkeley.edu/project/47768(Donations are tax-deductible for US taxpayers.) ********** In late August, I sent a letter to eClinicalMedicine, a Lancet journal, about an egregiously flawed paper ...
Trial By Error: Interview with Professor Chris Ponting on Building ME/CFS Research Infrastructure with PRIME
By David Tuller
By David Tuller, DrPH This is a crowdfunding month for UC Berkekely and Trial By Error. If you'd like to support my work, here's the link: https://crowdfund.berkeley.edu/project/47768(Donations are tax-deductible for US taxpayers.) ********** The UK Medical Research Council recently awarded £800,000 over four years to PRIME, a partnership between Action ...
Trial By Error: My Letter to Cochrane’s Chief Executive Officer
By David Tuller
By David Tuller, DrPH The other day, I posted yet another blog about Cochrane's deeply flawed 2019 review of exercise therapy for what it called chronic fatigue syndrome (CFS), and the organization's decision last December to abandon a planned update. Specifically, I was commenting on a response from the review's ...
